A Phase II Trial of Osimertinib in the Second-Line Treatment of Non-small Cell Lung Cancer with the EGFR T790M Mutation, Detected from Circulating Tumor DNA: LiquidLung-O-Cohort 2
Author:
Publisher
Korean Cancer Association
Subject
Cancer Research,Oncology
Link
http://e-crt.org/upload/pdf/crt-2018-387.pdf
Reference22 articles.
1. Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers
2. AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer
3. Osimertinib in Pretreated T790M-Positive Advanced Non–Small-Cell Lung Cancer: AURA Study Phase II Extension Component
4. Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
5. Osimertinib in UntreatedEGFR-Mutated Advanced Non–Small-Cell Lung Cancer
Cited by 41 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Liquid biopsy for the management of NSCLC patients under osimertinib treatment;Critical Reviews in Clinical Laboratory Sciences;2024-02-02
2. CDC6 may serve as an indicator of lung adenocarcinoma prognosis and progression based on TCGA and GEO data mining and experimental analyses;Oncology Reports;2024-01-03
3. Usefulness of bronchial washing fluid for detection of EGFR mutations in non-small cell lung cancer;Lung Cancer;2023-12
4. A novel neutrophil extracellular traps-related lncRNA signature predicts prognosis in patients with early-stage lung adenocarcinoma;Annals of Medicine;2023-11-19
5. The Utility of ctDNA in Lung Cancer Clinical Research and Practice: A Systematic Review and Meta-Analysis of Clinical Studies;Cancer Investigation;2023-06-18
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3